Abstract:
BACKGROUND:Rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), was approved for HIV-1 infected, antiretroviral treatment-naive adults based on data from two Phase III trials. In the screening population, the prevalence of 49 NNRTI resistance-associated mutations (RAMs) and the impact of allowed NNRTI RAMs on virological response to an RPV- or efavirenz (EFV)-containing regimen were analysed. METHODS:ECHO and THRIVE were global, Phase III, doubleblind, double-dummy, randomized trials in antiretroviral treatment-naive, HIV-1-infected adults to determine whether RPV 25 mg once daily had non-inferior efficacy versus EFV 600 mg once daily, both given with tenofovir/emtricitabine (ECHO) or tenofovir/emtricitabine, zidovudine/lamivudine or abacavir/lamivudine (THRIVE). The prevalence of 49 NNRTI RAMs, including the predefined list of 39 NNRTI RAMs used to exclude patients with potential resistance to RPV or EFV, was investigated at screening by population sequencing (including mixtures) using the virco(®)TYPE HIV-1 genotyping assay. RESULTS:Of the 1,796 screened patients in whom genotypic resistance results were available, 372 (21%) had NNRTI RAMs. Of 527 screening failures, 148 (28%) were due to the presence of NNRTI RAMs. The presence of allowed NNRTI RAMs was associated with comparable response rates to the overall population (RPV 84.3% versus EFV 82.3%, intent-to-treat time-to-loss-of-virological-response): V90I (82.4% and 100% for RPV and EFV, respectively), V106I (85.7% and 93.3%), V179I (87.7% and 94.0%) and V189I (100.0% and 88.9%). CONCLUSIONS:Analysis of the ECHO and THRIVE screened population suggests that transmitted NNRTI resistance is prevalent in treatment-naive patients but prevalence of the 15 RPV RAMs remains low. The four allowed NNRTI RAMs present at baseline did not affect RPV response at week 48.
journal_name
Antivir Therjournal_title
Antiviral therapyauthors
Vingerhoets J,Rimsky L,Van Eygen V,Nijs S,Vanveggel S,Boven K,Picchio Gdoi
10.3851/IMP2358subject
Has Abstractpub_date
2013-01-01 00:00:00pages
253-6issue
2eissn
1359-6535issn
2040-2058journal_volume
18pub_type
杂志文章,随机对照试验abstract::There are many potential reasons for increased liver-related mortality in HIV-hepatitis B virus (HBV) coinfection compared with either infection alone. HIV infects multiple cells in the liver and might potentially alter the life cycle of HBV, although evidence to date is limited. Unique mutations in HBV have been defi...
journal_title:Antiviral therapy
pub_type: 杂志文章,评审
doi:
更新日期:2009-01-01 00:00:00
abstract:BACKGROUND:Rilpivirine-based regimens are now preferred or alternative first-line regimens according to many HIV treatment guidelines. Recently, a surveillance study conducted in Argentina determined that prevalence of pretreatment resistance to first-generation non-nucleoside reverse transcriptase inhibitors (NNRTIs) ...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP3147
更新日期:2017-01-01 00:00:00
abstract:BACKGROUND:Quantification of HBsAg in serum may be of clinical importance in predicting HBsAg seroconversion and complete response to treatment. METHODS:Serum HBsAg was quantified by ADVIA Centaur in 63 patients with HBeAg-negative chronic hepatitis B (CHBe-). A total of 42 had received interferon-alpha2b (IFN-alpha2b...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:
更新日期:2007-01-01 00:00:00
abstract:BACKGROUND:Endothelial progenitor cells (EPCs) are involved in the endothelium repair. Low circulating EPC levels are predictive of cardiovascular events in HIV-negative subjects. The impact of HIV infection on EPCs, and the role of EPCs in HIV-associated cardiovascular disease, is not known. We hypothesized that circu...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP2013
更新日期:2012-01-01 00:00:00
abstract:BACKGROUND:Mutations in the genome of HIV conferring drug resistance are a major reason for the failure of antiretroviral therapy, but they often compromise viral fitness. Protease (PR) cleavage site (CS) mutations could compensate for impaired replication capacity of drug-resistant viruses. PATIENTS AND METHODS:We an...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:
更新日期:2006-01-01 00:00:00
abstract::HIV-HBV-coinfected patients require optimal control of viral replication in order to prevent the development of severe comorbidities, such as liver cirrhosis and hepatocellular carcinoma. The genetic diversity of HBV is a poorly investigated factor of such viral replication in HIV-infected hosts. HBV genome diversity ...
journal_title:Antiviral therapy
pub_type: 杂志文章,评审
doi:10.3851/IMP1495
更新日期:2010-01-01 00:00:00
abstract:BACKGROUND:The objective of this study was to compare indinavir peak plasma (Cmax) values after administration of indinavir/ritonavir 800/100 mg on an empty stomach or with food. High indinavir Cmax values have been associated with indinavir-related nephrotoxicity. METHODS:This was an open-label, randomized, two-treat...
journal_title:Antiviral therapy
pub_type: 临床试验,杂志文章,随机对照试验
doi:
更新日期:2003-08-01 00:00:00
abstract:BACKGROUND:In HIV-infected patients, therapeutic drug monitoring (TDM) of antiretroviral drugs is recommended in special populations and in specific situations to optimize therapy. Currently, TDM is performed via measurement of drug plasma concentrations; however, dried blood spots (DBS) may offer a patient friendly an...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP2501
更新日期:2013-01-01 00:00:00
abstract:BACKGROUND:Protease inhibitors (PI) have relatively low penetration into the genital tract, raising concerns about the potential for genital HIV RNA shedding in patients taking PI-based regimens, particularly PI monotherapy (PI-mono). METHODS:We measured HIV RNA and PI drug concentrations in samples of semen, cervico-...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP3340
更新日期:2020-01-01 00:00:00
abstract:BACKGROUND:Limited data suggest that glycated haemoglobin (haemoglobin A1c; A1C) values might not reflect glycaemic control accurately in HIV-infected individuals with diabetes. METHODS:We evaluated repeated measures of paired fasting glucose and A1C values in 315 HIV-infected and 109 HIV-uninfected diabetic participa...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP1557
更新日期:2010-01-01 00:00:00
abstract::To our knowledge, there are no previously published cases of enteroviral infection complicated by pityriasis lichenoides et varioliformis acuta (PLEVA). A 30-year-old woman is reported with a severe form of PLEVA, preceded by hand, foot and mouth disease. Immunosuppressive treatment with cyclosporin A resulted in rapi...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP3012
更新日期:2016-01-01 00:00:00
abstract:OBJECTIVE:To estimate the treatment and health care costs of HIV infection or AIDS in France during the era of highly active antiretroviral therapy (HAART). DESIGN:We used a clinical database of HIV-infected patients to calculate the resource use and cost of care for different stages of HIV infection. Costs were incor...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:
更新日期:2002-12-01 00:00:00
abstract::The prevention of mother-to-child transmission of HIV-1 during breastfeeding is a major concern in resource-poor settings where alternatives to breast milk may be unaffordable, unsafe and limited by social stigma. The use of triple-drug antiretroviral regimens initiated during pregnancy and continued throughout breast...
journal_title:Antiviral therapy
pub_type: 评论,杂志文章
doi:10.3851/IMP2314
更新日期:2012-01-01 00:00:00
abstract::Chronic infection with HBV or HCV can lead to the development of hepatocellular carcinoma (HCC). The major risk factors for HBV-related HCC are persistent presence of hepatitis B e antigen (HBeAg) and/or high serum HBV DNA levels, and cirrhosis. The major risk factor for HCV-related HCC is cirrhosis. One randomized do...
journal_title:Antiviral therapy
pub_type: 杂志文章,评审
doi:10.3851/IMP1895
更新日期:2011-01-01 00:00:00
abstract:BACKGROUND:Drug efflux (for example, P-glycoprotein [P-gp], multidrug resistance-associated proteins [MRPs] and breast cancer resistance protein [BCRP]) and influx (for example, human organic anion transporting polypeptide [hOCTP] or human organic anion transporting polypeptide [hOATP]) transporters alter the cellular ...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP1399
更新日期:2009-01-01 00:00:00
abstract:BACKGROUND:It remains unclear whether depression in chronic hepatitis B (CHB) and chronic hepatitis C (CHC) during pegylated interferon-based therapy is associated with the virus, drug or ethnic background. We aimed to perform a prospective study to evaluate the clinical course of depression and its predictors in conse...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP2441
更新日期:2013-01-01 00:00:00
abstract::Human papillomavirus (HPV) infections are a major human health problem; they are the cause of recurrent benign warts and of several cancers of the anogenital tract and head and neck region. Although there are two prophylactic HPV vaccines that could, if used universally, prevent as many as two-thirds of HPV-induced ca...
journal_title:Antiviral therapy
pub_type: 杂志文章,评审
doi:10.3851/IMP2612
更新日期:2013-01-01 00:00:00
abstract:BACKGROUND:This study aimed to evaluate whether low darunavir (DRV) minimum plasma concentration (Cmin) values contribute to virological outcomes during DRV/ritonavir monotherapy (mtDRV/rtv). METHODS:This was a prospective observational single-arm 96-week efficacy study in virologically suppressed subjects on triple t...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP2722
更新日期:2014-01-01 00:00:00
abstract:BACKGROUND:This study evaluates the added benefit when estimating antiretroviral drug resistance of combining all available resistance test results in a cumulative genotype relative to using the latest genotype alone. METHODS:The prevalence of resistance and genotypic sensitivity scores (GSS) predicted by the latest a...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP1753
更新日期:2011-01-01 00:00:00
abstract:BACKGROUND:Current stopping rules during pegylated interferon (peg-IFN)/ribavirin (RBV) treatment rely on week 12 HCV RNA response, but earlier identification of non-responders offers clinical and economic advantages. AIMS AND METHODS:To evaluate, among 129 HCV-genotype-1-infected, treatment-naive patients receiving p...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:
更新日期:2007-01-01 00:00:00
abstract::The current prevalence of cognitive impairment in HIV-infected individuals is surprisingly high, even in those with undetectable plasma HIV RNA. The aetiology is unknown but one possibility is inadequate control of persistent central nervous system (CNS) HIV infection. The CNS Penetration Effectiveness (CPE) rank has ...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP2951
更新日期:2015-01-01 00:00:00
abstract:OBJECTIVES:To assess potential pharmacokinetic (PK) interactions between atazanavir (ATV, 300 mg, once daily) and lopinavir (LPV, 400 mg, twice daily), both boosted by ritonavir (RTV, 100 mg). DESIGN:Two-parallel groups, addition of LPV in patients receiving ATV (n=6), and addition of ATV in patients receiving LPV (n=...
journal_title:Antiviral therapy
pub_type: 临床试验,杂志文章
doi:
更新日期:2006-01-01 00:00:00
abstract:OBJECTIVES:To evaluate whether fuzzy operators can be usefully applied to the interpretation of genotypic HIV-1 drug resistance by experts, and to improve the prediction of salvage therapy outcome by adapting interpretation rules of genotypic resistance on the basis of their association with virological response data. ...
journal_title:Antiviral therapy
pub_type: 杂志文章,多中心研究
doi:
更新日期:2004-08-01 00:00:00
abstract::All illnesses and, by association, all provision of health care in any setting have a cost, whether it is the direct cost to the consumer, to the provider (for example, a national health service) or the indirect cost to an employer or to society in lost production. Disease also has hidden or intangible costs of pain, ...
journal_title:Antiviral therapy
pub_type: 杂志文章,评审
doi:
更新日期:1999-01-01 00:00:00
abstract:BACKGROUND:Peripheral neuropathy (PN) in HIV-infected individuals is thought be due to a toxic effect on mitochondria induced by some nucleoside reverse transcriptase inhibitors (NRTI). METHODS:A time-to-event analysis was performed using data from the Delta trial to study the incidence of PN in HIV-infected individua...
journal_title:Antiviral therapy
pub_type: 杂志文章,随机对照试验
doi:
更新日期:2008-01-01 00:00:00
abstract:BACKGROUND:Lamivudine is widely used in patients with chronic hepatitis B virus (HBV) infection. In cirrhotic patients, long-term lamivudine therapy significantly reduced the risk of hepatocellular carcinoma (HCC). However, in a small but substantial portion of patients, HCC still developed despite lamivudine therapy. ...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:
更新日期:2009-01-01 00:00:00
abstract::The balance of virus production and clearance for untreated patients with chronic hepatitis C virus (HCV) results in a decline of viraemia when initiating active antiviral treatment. During the first phase of interferon-alpha therapy, after a delay of about 8-9 h, the kinetics of the viral load is characterized by a r...
journal_title:Antiviral therapy
pub_type: 杂志文章,评审
doi:
更新日期:2000-06-01 00:00:00
abstract::Varicella zoster virus (VZV) is less susceptible than herpes simplex virus to acyclovir. The optimal acyclovir regimen during VZV encephalitis remains unknown. We report two cases of acute renal failure after an increase in acyclovir dosage from 10 mg to 15 mg/kg/8 h during the treatment of VZV encephalitis according ...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP3313
更新日期:2019-01-01 00:00:00
abstract::Here, we describe a case of an HIV-infected patient with right lower limb oedema that appeared after initiation of tenofovir and emtricitabine treatment. The patient was fully investigated by serial heart and vessel echo-Doppler examination. Oedema of the lower limb was attributed to a transient drug-induced fivefold ...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP1302
更新日期:2009-01-01 00:00:00
abstract:BACKGROUND:With the advent of the protease inhibitors boceprevir and telaprevir a novel therapy approach for HCV genotype 1 infected subjects has become standard of care. Quantification of HCV viral load (VL) represents an important predictor of treatment response. METHODS:Two different real-time PCR platforms, the CO...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP2723
更新日期:2014-01-01 00:00:00